Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06233799 · ClinicalTrials.gov registry record · Phase 3

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

A Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by National Institute on Drug Abuse (NIDA).

Recruiting
Registry status
Phase 3
Development phase
360
Enrollment target
11
Study locations

NCT06233799: Recruiting Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by National Institute on Drug Abuse (NIDA).

NCT06233799 is a Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse that is actively recruiting participants, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 360 participants, above the 86-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (319% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06233799, a Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse, is actively recruiting participants, sponsored by National Institute on Drug Abuse (NIDA).

RECRUITING
Registry status
Phase 3
Development phase
360 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

Primary Outcome

Participants will be administered four urine drug screen tests (two tests/week) during the evaluation period. (i.e., Weeks 11-12).

Interventions

  • DRUG extended-release naltrexone (XR-NTX)
  • DRUG extended release bupropion (BUP-XL) tablets (BUP-XL)
  • DRUG iPLB
  • DRUG oPLB

Study Locations (11)

California

  • University of California Los Angeles - Los Angeles
  • University of California at San Diego - San Diego

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Indiana

  • Indiana University - Indianapolis

Kansas

  • University of Kansas Medical Center - Kansas City

Minnesota

  • University of Minnesota - Minneapolis

Oregon

  • CODA - Portland

South Carolina

  • MUSC/BHS - Pickens

Tennessee

  • University of Tennessee - Memphis

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2024-07-01
Est. Completion 2027-04-30
Phase Phase 3

What NCT06233799 shows while recruiting

NCT06233799 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 86-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (319% higher).

The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 4 interventions - of which extended-release naltrexone (XR-NTX) is the first listed.

NCT06233799 lists 11 locations in 10 states (California, Arkansas, Indiana).

Frequently Asked Questions

What is clinical trial NCT06233799 about?

NCT06233799 is a clinical study titled "Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder". The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) ...

What is the current status of trial NCT06233799?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2024-07-01. Estimated completion is 2027-04-30.

What conditions does trial NCT06233799 study?

This clinical trial studies the following conditions: Methamphetamine-dependence, Methamphetamine Abuse.

What interventions are being tested in trial NCT06233799?

The interventions under investigation include: extended-release naltrexone (XR-NTX) (DRUG), extended release bupropion (BUP-XL) tablets (BUP-XL) (DRUG), iPLB (DRUG), oPLB (DRUG).

Who is sponsoring clinical trial NCT06233799?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06233799 being conducted?

This trial has 11 study locations across Arkansas, California, Indiana, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Methamphetamine-dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06233799's enrollment target sits among peer trials

360 2nd of 18 the highest of 18 other Methamphetamine-dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Methamphetamine-dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04160000 · 360 participants · Phase 4

    Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06233799, the US trial registry maintained by the National Library of Medicine. NCT06233799 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.